Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Gabather

0.043

 

SEK

 

+4.88 %

Less than 1K followers

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
+4.88%
+6.44%
-65.6%
-59.65%
-66.37%
-89.87%
-97.19%
-96.84%
-98.98%

Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Read more
Market cap
10.16M SEK
Turnover
5.44K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
30/6
2025

General meeting '25

28/8
2025

Interim report Q2'25

27/11
2025

Interim report Q3'25

All
Press releases
3rd party
ShowingAll content types
Regulatory press release5/28/2025, 6:30 AM

Gabather AB: Gabather publicerar delårsrapport 1 januari - 31 mars 2025

Gabather
Regulatory press release5/26/2025, 6:30 AM

Gabather AB: KALLELSE TILL ÅRSSTÄMMA I GABATHER AB (PUBL)

Gabather
Regulatory press release5/23/2025, 7:49 PM

Gabather AB offentliggör årsredovisning för räkenskapsåret 2024

Gabather

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/22/2025, 11:30 AM

Gabather AB and MINDIG Reveal Promising fMRI Results Demonstrating GT-002's Lasting Impact on Brain Activity

Gabather
Regulatory press release3/31/2025, 2:00 PM

Gabather AB: Byte av Certified Adviser (CA) till Västra Hamnen Corporate Finance

Gabather
Regulatory press release3/26/2025, 3:15 PM

Gabather AB: Gabathers företrädesemission är registrerad - omvandling av BTU till aktier och teckningsoptioner

Gabather
Regulatory press release3/20/2025, 2:54 PM

Gabather AB: Gabather offentliggör slutligt utfall i företrädesemissionen

Gabather
Regulatory press release3/18/2025, 6:30 PM

Gabather AB: Gabather offentliggör preliminärt utfall i företrädesemission en och informerar om bolagets rörelsekapital

Gabather
Regulatory press release3/17/2025, 9:42 AM

Gabather AB: Sista teckningsdag i Gabathers teckningsperiod

Gabather
Press release3/6/2025, 1:07 PM

Analyst Group: Analyst Group Interview Gabather's CEO Michael-Robin Witt

Gabather
Third party research3/6/2025, 8:55 AM

Gabather: Redefining Cognitive Disorder Treatment - Analyst Group

Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting cognitive dysfunction. With a fully funded schizophrenia Phase II trial and a planned expansion into Phase II...

Gabather
Press release3/6/2025, 8:12 AM

Analyst Group: Analyst Group Comment on Gabather

Gabather
Regulatory press release3/4/2025, 7:30 AM

Gabather AB: Idag inleds teckningsperioden i Gabathers företrädesemission och bolaget bjuder in till webbkonferenser

Gabather
Regulatory press release2/28/2025, 9:30 AM

Gabather AB: Gabather offentliggör prospekt med anledning av förestående företrädesemission

Gabather
Regulatory press release2/21/2025, 2:29 PM

Gabather AB: Kommuniké från extra bolagsstämma i Gabather

Gabather
Regulatory press release2/21/2025, 7:30 AM

Gabather AB: Gabather publicerar bokslutskommuniké 1 Januari - 31 december 2024

Gabather
Regulatory press release2/14/2025, 1:13 PM

Gabather AB: Grönt ljus för fas II-klinisk prövning av GT-002

Gabather
Regulatory press release2/11/2025, 11:23 AM

Förändring i Gabather ABs valberedning

Gabather
Regulatory press release2/6/2025, 12:50 PM

Gabather AB: Gabather offentliggör utfall av nyttjande av teckningsoptioner av serie TO 6

Gabather
Regulatory press release1/20/2025, 10:00 AM

Gabather AB: Teckningskursen för utnyttjande av teckningsoptioner av serie TO 6 i Gabather har fastställts till 0,38 SEK per aktie inför teckningsperioden som inleds den 21 januari 2025

Gabather
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team